Patents by Inventor Jonas Karl-Josef Honer

Jonas Karl-Josef Honer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CCR8 ANTIBODIES AND USES THEREOF
    Publication number: 20250171549
    Abstract: The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: January 28, 2025
    Publication date: May 29, 2025
    Applicants: AMGEN INC., AMGEN RESEARCH (MUNICH) GmbH
    Inventors: Nathan William PIERCE, Agnieszka KIELCZEWSKA, Wentao CHEN, Olivier NOLAN-STEVAUX, Darren L. BATES, Lisa WINKEL, Christoph DAHLHOFF, Tobias RAUM, Claudia BLUEMEL, Jonas Karl-Josef HONER
  • T CELL ENGAGER MOLECULES AND USES THEREOF
    Publication number: 20250129160
    Abstract: The present invention provides single chain T cell engager (TCE) molecules having an scFab that binds a target antigen and an scFv that binds CD3, and TCE molecules that bind CCR8 and CD3. Methods of treating cancer are also provided.
    Type: Application
    Filed: June 2, 2022
    Publication date: April 24, 2025
    Applicants: AMGEN RESEARCH (MUNICH) GmbH, AMGEN INC.
    Inventors: Johannes BROZY, Christoph DAHLHOFF, Tobias RAUM, Jochen S. PENDZIALEK, Lisa WINKEL, Marcus MUENZ, Nathan William PIERCE, Agnieszka KIELCZEWSKA, Wentao CHEN, Darren L. BATES, Claudia BLUEMEL, Jonas Karl-Josef HONER
  • Anti-CCR8 antibodies and uses thereof
    Patent number: 12258411
    Abstract: The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: March 25, 2025
    Assignees: AMGEN INC., AMGEN RESEARCH (MUNICH) GmbH
    Inventors: Nathan William Pierce, Agnieszka Kielczewska, Wentao Chen, Olivier Nolan-Stevaux, Darren L. Bates, Lisa Winkel, Christoph Dahlhoff, Tobias Raum, Claudia Bluemel, Jonas Karl-Josef Honer
  • MULTITARGETING ANTIGEN-BINDING MOLECULES FOR USE IN PROLIFERATIVE DISEASES
    Publication number: 20220403035
    Abstract: The present invention provides bispecific antigen-binding molecules characterized by comprising a first and a second domain, each binding to any of CS1, BCMA, CD20, CD22, FLT3, CD123, CLL1, MSLN, CDH3 or EpCAM, a third domain binding to an extracellular epitope of the human and the Macaca CD3? chain and optionally a fourth domain, which is a Fc modality. Moreover, the invention provides a polynucleotide, encoding the antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 22, 2022
    Inventors: Jonas Anlahr, Tara Arvedson, Julie Bailis, Matthew Chun, Igor D'Angelo, Christopher Dahlhoff, Stephanie Everts, Mattias Friedrich, Lars Gaedtke, Patrick Hoffmann, Rebecca Goldstein, Jonas Karl-Josef Honer, Roman Kischel, Matthias Klinger, Peter Kufer, Markus Muenz